Methods
A retrospective review of the hospital cancer registry from 2000-2010 was performed. HIV status of identified lung cancer patients was assessed. Demographics, stage of cancer, and outcome were recorded for HIV+ and HIV-patients. Data were analyzed using SAS 9.1.
Results
Over the 10-year period, 1250 lung cancer cases were identified (75HIV+, 205 HIV-, and 970 unknown HIV status. There were 20 women (W+) and 55 men (M+) with HIV, and 85 women (W-) and 120 men (M-) who are HIV-. There were significantly more men tested for HIV at cancer diagnosis than women (p=0.0001). The distribution of lung cancer type is similar among the HIV+ and HIV-. Median age at cancer diagnosis is not significantly different with W+(50 years old), W-(55) , M+(55) and M-(58 ). Presentation at stage IIIB or IV occurred in 69%W+, 67% W, 68%M+ and 73%M-. There is no difference of median CD4 (W+=233, M+=159, p=0.1) or HAART use at cancer diagnosis among M+( 53%) or W+( 63%) , p=0.4. The median survival time for W+(386 days), M+(192 days ), W-(475 day) and M-(247 days) . There is trend for longer survival for W+ versus M+ (log rank p=0.07), as well as W-versus M-(log rank p=0.06), but no difference for W+ vsW-(LR p=0.7) or M+ vs M-(LR p=0.8).
Conclusion
The experience in our hospital reveals that in the HAART era, there does not seem to be a difference in lung cancer presentation among HIV+ or HIV-patients, and that there is a trend for better survival among women compared to men.whether HIV+ or HIV-. Further studies are needed to explain this gender difference.
